FI943565A - Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus - Google Patents

Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus Download PDF

Info

Publication number
FI943565A
FI943565A FI943565A FI943565A FI943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical composition
composition containing
novel anticoagulant
anticoagulant polypeptides
Prior art date
Application number
FI943565A
Other languages
English (en)
Swedish (sv)
Other versions
FI943565A0 (fi
Inventor
Reinhard Fleer
Alain Fournier
Jean-Dominique Guitton
Gerard Jung
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943565A publication Critical patent/FI943565A/fi
Publication of FI943565A0 publication Critical patent/FI943565A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI943565A 1992-01-31 1994-07-29 Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus FI943565A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201066A FR2686901A1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000087 WO1993015200A1 (fr) 1992-01-31 1993-01-28 Polypeptides antithrombotiques, antagonistes de la liaison du vwf aux plaquettes et/ou au sous-endothelium

Publications (2)

Publication Number Publication Date
FI943565A true FI943565A (fi) 1994-07-29
FI943565A0 FI943565A0 (fi) 1994-07-29

Family

ID=9426193

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943565A FI943565A0 (fi) 1992-01-31 1994-07-29 Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus

Country Status (7)

Country Link
EP (1) EP0625199A1 (fi)
JP (1) JPH07503369A (fi)
CA (1) CA2126092A1 (fi)
FI (1) FI943565A0 (fi)
FR (1) FR2686901A1 (fi)
NO (1) NO942840L (fi)
WO (1) WO1993015200A1 (fi)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
CA2469846A1 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2521826C (en) 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
ES2372495T3 (es) 2003-11-13 2012-01-20 Hanmi Holdings Co., Ltd Método para la producción en masa de la región constante de inmunoglobulina.
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP5651285B2 (ja) 2005-02-15 2015-01-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
EP2573114B1 (en) 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP3058972A1 (en) 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX2009012341A (es) 2007-05-14 2010-02-17 Medimmune Llc Metodos para reducir niveles de eosinofilos.
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
JP5571567B2 (ja) 2007-12-21 2014-08-13 メディミューン リミテッド インターロイキン−４受容体α（ＩＬ−４Ｒα）−１７３に対する結合メンバー
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
EP2837388A1 (en) 2008-08-05 2015-02-18 Novartis AG Compositions and methods for antibodies targeting complement protein C5
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
ES2719496T3 (es) 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
RU2503688C2 (ru) 2009-04-22 2014-01-10 Алтеоген, Инк Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
RU2519031C1 (ru) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Жидкие препаративные формы для длительно действующего конъюгата g-csf
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
MX2013002255A (es) 2010-08-27 2013-07-03 Stem Centrx Inc Moduladores de proteina de notum y metodos de uso.
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2016123839A (ru) 2010-12-08 2018-11-30 АббВай Стемсентркс ЭлЭлСи Новые модуляторы и способы их применения
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773665A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
KR102159843B1 (ko) 2011-12-21 2020-09-24 노파르티스 아게 인자 p를 표적화하는 항체에 대한 조성물 및 방법
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US9365646B2 (en) 2012-12-05 2016-06-14 Novartis Ag Compositions and methods for antibodies targeting EPO
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
MX2016002547A (es) 2013-08-28 2016-06-17 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP6614582B2 (ja) 2014-04-04 2019-12-04 バイオノミクス インコーポレイテッド Ｌｇｒ５に結合するヒト化抗体
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
MX2017015690A (es) 2015-06-05 2018-07-06 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
DK3347377T3 (da) 2015-09-09 2021-05-10 Novartis Ag Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
CN109069623A (zh) 2015-12-18 2018-12-21 诺华股份有限公司 靶向CD32b的抗体及其使用方法
CA3009001A1 (en) 2016-01-11 2017-07-20 Universitat Zurich Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
JP2019509322A (ja) 2016-03-22 2019-04-04 バイオノミクス リミテッド 抗ｌｇｒ５モノクローナル抗体の投与
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
BR112018073669A2 (pt) * 2016-05-20 2019-02-26 Octapharma Ag proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
CA3027651A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
AU2018218557B9 (en) 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3976181A1 (en) 2019-05-24 2022-04-06 Sanofi Methods for treating systemic sclerosis
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255206B1 (en) * 1986-05-30 1995-03-22 The Scripps Research Institute Peptides that inhibit von Willebrand factor binding
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
CA2094259A1 (en) * 1990-10-17 1992-04-18 Zaverio M. Ruggeri Therapeutic fragments of von willebrand factor
AU1757592A (en) * 1991-03-27 1992-11-02 Scripps Research Institute, The Therapeutic fragments of von willebrand factor
WO1993000357A1 (en) * 1991-06-28 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic polypeptides based on von willebrand factor

Also Published As

Publication number Publication date
NO942840D0 (no) 1994-07-29
EP0625199A1 (fr) 1994-11-23
NO942840L (no) 1994-09-29
CA2126092A1 (fr) 1993-08-05
FI943565A0 (fi) 1994-07-29
JPH07503369A (ja) 1995-04-13
FR2686901A1 (fr) 1993-08-06
WO1993015200A1 (fr) 1993-08-05

Similar Documents

Publication Publication Date Title
FI943565A (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
DE10199066I1 (de) Pharmazeutische Zusammensetzung
IL95155A0 (en) 1h-indazole-3-carboxamides,their preparation and pharmaceutical compositions containing them
IL95640A0 (en) 1-cycloalkylpiperidines,their preparation and pharmaceutical compositions containing them
IT1232677B (it) Composizione farmaceutica contenente ranitidina
EE03111B1 (et) Glükokortikosteroidi epimeerid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
IL94556A0 (en) Hydroxypropylamines,their preparation and pharmaceutical compositions containing them
FI951789A (fi) Uusia taksaanijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
FI893643A0 (fi) Farmaceutiska kompositioner.
IL86876A0 (en) Polypeptides,their preparation and pharmaceutical composition containing them
FI961938A0 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI960316A (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
IL91709A0 (en) Substituted thienopyrans,their preparation and pharmaceutical compositions containing them
IL92889A0 (en) Benzene derivatives,their preparation and pharmaceutical compositions containing them
IL92326A0 (en) Substituted oxadiamino-butanes,their preparation and pharmaceutical compositions containing them
FR2636063B1 (fr) Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
IL91003A0 (en) Proteins,their production and pharmaceutical compositions containing them
DK336489A (da) Farmaceutisk praeparat
IL99009A0 (en) Polypeptides,their preparation and pharmaceutical compositions containing them
IL91002A0 (en) Modified proteins,their production and pharmaceutical compositions containing them
IL84509A0 (en) Pyrrolo-benzimidazoles,their preparation and pharmaceutical composition containing them
IL95563A0 (en) Substituted amino-pyridines,their preparation and pharmaceutical compositions containing them
IL93479A0 (en) 1h-imidazole-1-acetamides,their preparation and pharmaceutical compositions containing them
IT1224244B (it) Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano
KR860005809A (ko) 3--1h-인다졸, 이의 제조방법 및 이들 화합물을 함유하는 약제학적 조성물

Legal Events

Date Code Title Description
FD Application lapsed